Rudd CE - Search Results

1

Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy.

Bartish M, Del Rincón SV, Rudd CE, Saragovi HU. Bartish M, et al. Among authors: rudd ce. Front Immunol. 2020 Sep 29;11:564499. doi: 10.3389/fimmu.2020.564499. eCollection 2020. Front Immunol. 2020. PMID: 33133075 Free PMC article. Review.

2

Glycogen Synthase Kinase 3 Inactivation Compensates for the Lack of CD28 in the Priming of CD8⁺ Cytotoxic T-Cells: Implications for anti-PD-1 Immunotherapy.

Taylor A, Rudd CE. Taylor A, et al. Among authors: rudd ce. Front Immunol. 2017 Dec 11;8:1653. doi: 10.3389/fimmu.2017.01653. eCollection 2017. Front Immunol. 2017. PMID: 29312284 Free PMC article.

3

CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy.

Brunner-Weinzierl MC, Rudd CE. Brunner-Weinzierl MC, et al. Among authors: rudd ce. Front Immunol. 2018 Nov 27;9:2737. doi: 10.3389/fimmu.2018.02737. eCollection 2018. Front Immunol. 2018. PMID: 30542345 Free PMC article. Review.

4

Advances in T-cell co-receptor biology and cancer immunotherapy.

Rudd CE. Rudd CE. Semin Immunol. 2019 Apr;42:101281. doi: 10.1016/j.smim.2019.101281. Semin Immunol. 2019. PMID: 31604538 No abstract available.

5

A new perspective in cancer immunotherapy: PD-1 on myeloid cells takes center stage in orchestrating immune checkpoint blockade.

Rudd CE. Rudd CE. Sci Immunol. 2020 Jan 3;5(43):eaaz8128. doi: 10.1126/sciimmunol.aaz8128. Sci Immunol. 2020. PMID: 31901075 Review.

6

GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response.

Rudd CE. Rudd CE. Front Immunol. 2020 Jun 26;11:1638. doi: 10.3389/fimmu.2020.01638. eCollection 2020. Front Immunol. 2020. PMID: 32695123 Free PMC article. Review.

7

Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.

Huang F, Gonçalves C, Bartish M, Rémy-Sarrazin J, Issa ME, Cordeiro B, Guo Q, Emond A, Attias M, Yang W, Plourde D, Su J, Gimeno MG, Zhan Y, Galán A, Rzymski T, Mazan M, Masiejczyk M, Faber J, Khoury E, Benoit A, Gagnon N, Dankort D, Journe F, Ghanem GE, Krawczyk CM, Saragovi HU, Piccirillo CA, Sonenberg N, Topisirovic I, Rudd CE, Miller WH Jr, Del Rincón SV. Huang F, et al. Among authors: rudd ce. J Clin Invest. 2021 Apr 15;131(8):e140752. doi: 10.1172/JCI140752. J Clin Invest. 2021. PMID: 33690225 Free PMC article.

8

Effective chimeric antigen receptor T cells against SARS-CoV-2.

Guo X, Kazanova A, Thurmond S, Saragovi HU, Rudd CE. Guo X, et al. Among authors: rudd ce. iScience. 2021 Nov 19;24(11):103295. doi: 10.1016/j.isci.2021.103295. Epub 2021 Oct 16. iScience. 2021. PMID: 34693218 Free PMC article.

9

Editorial: T-Cell Signaling Networks in Health and Disease.

Rudd CE, Merida I, Hawse W. Rudd CE, et al. Front Immunol. 2022 Apr 6;13:875580. doi: 10.3389/fimmu.2022.875580. eCollection 2022. Front Immunol. 2022. PMID: 35464446 Free PMC article. No abstract available.

10

Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications.

Krueger J, Rudd CE, Taylor A. Krueger J, et al. Among authors: rudd ce. Semin Immunol. 2019 Apr;42:101295. doi: 10.1016/j.smim.2019.101295. Semin Immunol. 2019. PMID: 31604533 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

205 results

Search Page